Oncoinvent Reports the First Patient Dosing with Radspherin in its P-II Clinical Evaluation for Ovarian Cancer
Shots:
- Oncoinvent has dosed the first patient with radspherin in its P-II study to treat peritoneal carcinomatosis from ovarian cancer. It recently received the US FDA’s FTD for the same
- The P-II trial is to evaluate the safety & efficacy of radspherin to treat peritoneal metastasis from ovarian cancer, with 1EP being PFS compared b/w patients receiving Radspherin post-surgery & CT vs those receiving only surgery & CT. Radspherin was well-tolerated without any DLTs at 7MBq in P-I/IIa study
- Radspherin (intraperitoneal) is a radiopharmaceutical intended to treat cancer metastasized to body cavities & uses calcium carbonate microparticles containing radium-224 to deliver potent alpha-particle radiation. Also being studied for peritoneal metastases from colorectal cancer
Ref: Oncoinvent | Image: Oncoinvent
Related News:- Aurigene Oncology Reports Results from the P-I (SWASTH) Trial of Ribrecabtagene Autoleucel for Multiple Myeloma in India
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
